

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2021/0403598 A1 Weisser et al.

Dec. 30, 2021 (43) **Pub. Date:**

(54) **BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2**

(71) Applicant: **Zymeworks Inc.**, Vancouver (CA)

(72) Inventors: Nina E. Weisser, Delta (CA); Gordon Yiu Kon NG, Vancouver (CA); Grant Raymond Wickman, Vancouver (CA); Surjit Bhimarao Dixit, Richmond (CA); Eric Escobar-Cabrera, Vancouver (CA); Mario Sanches,

Vancouver (CA)

(21) Appl. No.: 17/184,508

(22) Filed: Feb. 24, 2021

Related U.S. Application Data

- (63) Continuation of application No. 15/036,176, filed on May 12, 2016, now Pat. No. 10,947,319, filed as application No. PCT/CA2014/051140 on Nov. 27,
- (60) Provisional application No. 61/910,026, filed on Nov. 27, 2013, provisional application No. 62/000,908, filed on May 20, 2014, provisional application No. 62/009,125, filed on Jun. 6, 2014.

Publication Classification

(51) Int. Cl. C07K 16/32 (2006.01)A61K 47/68 (2006.01)A61K 39/395 (2006.01)A61K 45/06 (2006.01)C07K 16/30 (2006.01)G01N 33/574 (2006.01)

U.S. Cl.

C07K 16/32 (2013.01); A61K 47/6803 CPC (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6869 (2017.08); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); C07K 16/3015 (2013.01); C07K 16/3069 (2013.01); G01N 33/57492 (2013.01); A61K 39/39558 (2013.01)

(57)ABSTRACT

Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.

Specification includes a Sequence Listing.